Skip to main content
Premium Trial:

Request an Annual Quote

Intermountain's ICG100 ONCO Focus Panel

Intermountain Precision Genomics, a cancer sequencing service provided by Intermountain Healthcare, is now offering the ICG100 ONCO Focus Panel. The next-generation sequencing panel analyzes five genes, KRAS, BRAF, NRAS, EGFR, and KIT, and is a leaner offering than the ICG100 Comprehensive Cancer panel which gauges 162 genes. Intermountain said that the five-gene panel requires as little as 20 nanograms of DNA, or between 5,000 and 8,000 cells, and has a two-day turnaround time, as opposed to the two weeks it takes to get back results from the comprehensive panel. The ICG100 ONCO Focus Panel evaluates genes that are frequently mutated in melanoma, lung, and colon cancers.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more